Local biotechs continue to attract funding. Boston startup MOMA Therapeutics recently completed a $150 million Series B financing. “Since our launch in 2020, MOMA has advanced our novel drug discovery platform, generated multiple high-impact oncology programs and bolstered our exceptional team. Through these achievements we are developing an explicit understanding of the dynamic conformational changes of molecular […]

GSK has agreed to acquire Cambridge-based Affinivax for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones. Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines. The transaction is expected to close in Q3 2022. Pneumococcal disease includes pneumonia, […]

The Massachusetts Biotechnology Council (MassBio) has released a study identifying workforce needs, expectations, and challenges across the Massachusetts life sciences industry. Findings from 129 biopharma companies show that 78 percent expect to grow their workforce over the next 12 months with both entry- and non-entry-level new hires, with most also having experienced difficulty in filling […]

A bid led by top government, business, higher education and life sciences officials to bring a federal biomedical research agency to Massachusetts has launched with a meeting at the UMass Club in Boston. Gov. Charlie Baker, Congressman Richard Neal, University of Massachusetts President Marty Meehan and MassBio CEO Joe Boncore are leading the effort to […]